IJHSR
ijhighschoolresearch.org
REVIEW ARTICLE

Bacteriophage Therapy: A Double-Edged Sword in Modern Medicine

Ananya Anand

Adlai E. Stevenson High School, 1 Stevenson Dr, Lincolnshire, IL, 60069, USA; ananya.anand319@gmail.com

ABSTRACT: Invented in the 20th century, antibiotics revolutionized the treatment of bacterial infections and remain the standard of care today. However, the rising threat of antimicrobial resistance (AMR) has renewed scientific interest in phage therapies (PTs). PTs are treatments that employ bacteriophages, viruses that naturally target bacteria, and could be used as alternatives to antibiotics. While PTs were developed around the same time as antibiotics, they fell out of use in Western medicine due to logistical and regulatory factors. Recent research underlines advantages that PTs have been purported to have, including self-replication capabilities, high specificity, biofilm penetration, and synergistic activity when administered alongside antibiotics. Nonetheless, limitations remain, such as complex formulation requirements, pharmaceutical unknowns, and significant regulatory hurdles. Clinical trials indicate that while PTs are generally safe and effective, they are not reliably superior to antibiotics. Additionally, methodological inconsistencies between studies hinder data synthesis, indicating that the field is still in its infancy. Surveys on current patient and clinician attitudes indicate that while many are receptive to trying PT, most are not initially familiar with PT. Overall, while PT is a promising response to AMR, trial standardization, consistent clinical protocols, and regulatory development are still necessary for it to achieve more prolific use.

KEYWORDS: Biomedical and Health Sciences, Genetics and Molecular Biology of Disease, Bacteriophage Therapy, Antimicrobial Resistance.

Introduction

Following their discovery in the 20th century, antibiotics rapidly became the standard treatment for bacterial infections. However, bacteria soon began to develop resistance to these new drugs. Antibiotic resistance has rapidly emerged as one of the most pressing concerns of the 21st century. The widespread and often indiscriminate use of antibiotics in clinical settings has accelerated the evolution of antibiotic-resistant strains of pathogenic bacteria.[1] As a result of this, previously treatable infections are becoming increasingly difficult to tackle. Currently, 700,000 annual deaths are a result of antibiotic-resistant bacteria (ARB), and this figure is projected to increase to over 10 million deaths per year by 2050.[2]

As a response to the diminishing effectiveness of traditional antibiotics, new research is exploring bacteriophage therapies as a mechanism to combat ARBs or work as an adjunct treatment with antibiotics to produce enhanced synergistic results.[3] Bacteriophages–viruses that specifically work to infect bacteria–were first discovered over a century ago, and were originally used therapeutically before antibiotics became widespread.[4-6] Now, with the growing ARB crisis, phages are being revisited as a mechanism to target specific pathogens, including ARBs, without disturbing the broader microbiome.[5,7]

Despite their advantages, phage therapies (PTs) also have their drawbacks. One concern stems from the potential that bacteria could evolve to be resistant to phages, similarly to how they are currently resistant to antibiotics.[8] Additionally, although current results seem promising, the safety of phage therapy in human clinical applications still appears to be somewhat uncertain, as noted by reviews conducted on animal and human *in vivo* studies.[9] Finally, there is also the risk that phages may indirectly facilitate the spread of bacterial antibiotic resistance genes through horizontal gene transfer, more specifically through transduction–a process in which phages can package and transfer genetic material, including antibiotic resistance genes (ARGs), and transfer them between bacteria, which can rapidly accelerate the spread and dissemination of ARBs.[10-12]

Based on this, it is apparent that while phages may be seen by some as a viable alternative to antibiotics in clinical settings, it is also true that their exact efficacy is somewhat uncertain. As a result of this dilemma, bacteriophage therapies currently stand as a promising but uncertain solution for combating antimicrobial resistance (AMR).[10]

This literature review aims to discuss the mechanisms behind phage therapy; explore the advantages and disadvantages of phage therapy to combat antibiotic resistance; examine studies of human clinical applications of phage therapy compiled across various databases; discuss current attitudes towards phage therapy; and discuss avenues for future research and clinical implementation of phage therapy to combat AMR.

Methodology

The objective of this study was to synthesize existing evidence regarding the evolution of PTs, their advantages, their disadvantages, current clinical trial results, and current clinical attitudes towards PT. This study was a literature review that employed a comprehensive search of databases–PubMed, ScienceDirect, and Clinicaltrials.gov–to identify and select papers

DOI: 10.36838/IJHSR816.22

for analysis. For PubMed, search terms such as *phage therapy* and *antibiotic resistance* were used to narrow down results, as well as filters that restricted the selection of papers to only those covering human clinical applications, such as clinical trials and case reports. For ScienceDirect, similar search terms were used, and filters were applied to restrict the selection to only research articles. Finally, Clinicaltrials.gov was searched using filters restricting the "Intervention/treatment" to only "Phage Therapy." All three databases were also filtered to ensure that only English-language articles published after 2020 would appear.

The papers from all three databases were then compiled in a spreadsheet in order to refine the selection. Duplicates were removed, as were papers that did not have the full body of text available, did not include their results, or did not directly concern phage therapy, antibiotic resistance, or ARGs. Veterinary trials were also excluded, as were studies aiming to characterize the bacteriophage itself as opposed to its applications in human clinical therapy.

Following this, a final selection of papers was compiled and analyzed. This involved the extraction of information on the historical development of antibiotics and phage therapies, the mechanisms behind both, the mechanisms behind antibiotic resistance, details pertaining to the benefits and limitations of phage therapy, patient and disease characteristics from PT trials, details of various phage treatments, and patient outcomes from PT.

No physical tools or materials were used in this study, as only online sources were consulted. Additionally, because this was a literature review, formal ethical approval was not required.

Discussion

The Basics of Bacteriophages:

Bacteriophages, often referred to as "phages," are a subclass of viruses that proliferate by infecting and replicating in bacteria. They are the most abundant biological entities on Earth, as they are found anywhere bacteria can exist, with the population containing an estimated ~10^{31} particles.[13]



Figure 1: Structure of a Phage. This figure shows a simplified diagram of a bacteriophage, including the head, DNA/RNA, collar, sheaths, tail fibers, base plates, and pins, which collectively allow for genome injection and bacterial cell lysis. These structural features guide the mechanistic basis of bacteriophages' therapeutic action. Adapted from https://doi.org/10.3390/coatings13030609.

As seen in Figure 1, structurally, phages are relatively simple; they are composed of genetic material (DNA or RNA, which can be either double or single stranded) that is enclosed in a capsid–an outer protein shell.[15] Phages may also possess elaborate structures such as contractile tails, base plates, pins, and tail fibers, which aid in host recognition and DNA injection. In the specific case of bacteriophages, they have tails that assist the phage in host recognition using receptor-binding proteins, as well as attaching and injecting material into the host. In the case of phage therapies, the host is the pathogenic bacterium being targeted by the therapy. After this step, the phage hijacks its host's cellular machinery to reproduce. Primarily, phages accomplish this in one of two ways, following either the lytic cycle or the lysogenic cycle.

In the lytic cycle, the virus's genetic material enters the cell, and cellular structures are rapidly redirected to new phage components, which are then assembled into viral progeny. This eventually leads to the host cell being either actively or passively lysed, and the progeny phages go on to infect other bacterial cells similarly. In the lysogenic cycle, phage genetic material is instead incorporated into the host's own genetic material or exists as an episomal plasmid. From there, the phage's genetic material is replicated by the bacteria and passed down to each bacterial daughter cell, progressively infiltrating the population of bacteria. These integrated phage genomes are called prophages. Prophages can convert to the lytic cycle, usually triggered by environmental changes.[15,16]



Figure 2: Process of Bacteriophage Infection. The figure demonstrates how bacteriophages rely on primary receptor attachment to infect host cells. The reliance on receptor-mediated attachment is the basis of both the precision of phage targeting and the narrow host range that complicates broader clinical applications. This image is adapted from https://doi.org/10.3390/v16030478.

When phages infect bacterial cells, they rely on highly specific receptors to gain entry into the cell. This process is illustrated in Figure 2, which demonstrates how infection of the bacterial cell cannot occur without proper receptor attachment. Due to this, each phage can only target a narrow range of hosts. As a result of this, they are particularly appealing for clinical therapies because of their potential to provide highly targeted action against pathogenic bacteria while leaving the rest of the microbiome otherwise unchanged.[5] However, they also act as a double-edged sword in the sense that the narrow host range may make it difficult to select phages for therapies.

Development Strategies of Phage Therapies:

Most bacteriophage therapies do not rely on one single phage, but instead use a combination of several phages known as phage cocktails. This is done for two primary biological realities. Firstly, phages have narrow host ranges due to their high receptor specificity, and although this can be an advantage when seeking targeted therapies, it also means that for complex infections, multiple types of bacteriophages will need to be employed to produce an effective therapy. Secondly, bacteria evolve resistance rapidly when subject to selective pressures, meaning that there is always the chance for a course of phage therapy to become ineffective against a bacterial strain that develops resistance. Having multiple phages in the cocktail mitigates the risk of resistance developing, depending on the bacterial context.[18] However, there are still some phage therapies that have utilized singular phages.

There are several different categories of phage therapy. One such category is "off-the-shelf" therapies, or fixed therapies, which are composed of predetermined phages that cover a predicted range of bacteria. The phages are screened for host-range breadth before being formulated into the cocktail. They are usually manufactured and then stocked by pharmaceutical isolation facilities, allowing for immediate use without having to isolate the pathogen.[19,20] This approach is attractive because it fits neatly into existing guidelines for drug approval pathways.

There are also modifiable phage therapies, which can be reviewed and adapted as needed. These resemble fixed cocktails, but they differ in the sense that they are periodically reformulated in order to retain efficacy against dominant clinical strains or as resistance patterns shift. Phages can be added, replaced, or modified to broaden the host range. This is a strategy that was commonly used in Georgia and Eastern Europe.[21]

Phage therapies can also come as personalized phage preparations. Phages are drawn from phage banks and then assayed against captured and cultured samples of a patient's infecting bacterial strains to see how well they respond to that particular patient's bacterial infection before later being synthesized into the cocktail, making for a more targeted treatment. The main consideration with this strategy seems to be the time it will take to prepare the treatment, but host range breadth is not a concern because specificity is the goal.

Genetic engineering, such as CRISPR gene editing or *in vitro* evolution ("phage training"), can also be used to broaden or optimize phage host range before the phages are incorporated into cocktails.[22] Engineered phages may also be constructed to express biofilm-degrading enzymes or to help enhance host cell killing ability. These modified phages will then be incorporated into the cocktail.

In practice, modified and fixed therapies will likely offer more efficient and immediate access to the treatment while also being compatible with regulatory guidelines. Personalized and engineered therapies allow for greater adaptability and specificity while also being more time-consuming and labor-intensive to produce.

Advantages of Phage Therapy:

There are many advantages that phage therapies have been purported to have over traditional courses of antibiotics. For instance, the fact that bacteriophages have such high host specificity means that phages can treat infections without wiping out the existing microbiome of a patient. This greatly reduces the risk of secondary infections by bacteria such as *Clostridium difficile*, which can occur after disruptions of the gut microbiome.[23] Additionally, their high host specificity is something that makes them particularly appealing when targeting antimicrobial-resistant bacteria, as genetic engineering can produce phages that are highly attuned to these resistant bacteria.[5]

Furthermore, lytic phages will replicate at the site of infection. This means that phage doses can amplify themselves, providing continuous therapeutic action and reducing the necessity of frequent readministrations. Once the infection has been eliminated, the phages will no longer have any hosts to infect, and consequently, their reproduction will halt, and they will be naturally cleared from the body.

Phages have also been proven to be highly effective against biofilms. Biofilms are described as communities of microbes that stick to a surface. These communities are encased in protective matrices and are often highly resistant to both the immune system and antibiotics. This is of particular importance for devices such as prosthetic implants and catheters, which are breeding grounds for biofilm development. Phage therapies, however, have been shown to penetrate and destroy these biofilms effectively.[24]

The coevolutionary nature between bacteria and bacteriophages also makes them uniquely suited to address the issue of antibiotic resistance. For instance, if a bacterium were to develop resistance to an antibiotic, an entirely new variety of antibiotic would have to be engineered or introduced in order to treat the infection. This process can take years or even decades and contrasts with bacteriophages, which can be easily genetically engineered to combat the resistant strain.[8] Phage therapy has also been shown to work synergistically with antibiotics, with combination therapy making treatments more effective and making it difficult for bacteria to develop resistance to either agent alone.[3]

Overall, these findings suggest that phage therapies offer several advantages over antibiotics in a variety of scenarios. Specifically, their narrow host range, self-replicating capabilities, and synergistic activity when applied alongside antibiotics prove them to be a promising adjunct or alternative treatment in situations where standard therapies may fail.

Disadvantages of Phage Therapy:

As previously mentioned, the high host specificity of bacteriophages can be simultaneously appealing and challenging. The process of finding phages that are uniquely suited to targeting specific bacterial strains can be time-consuming, costly, and especially troublesome in cases involving polymicrobial infections or in acute situations where immediate treatment is a necessity.[25] For phage therapy to be effective, hospitals would need to maintain large and well-characterized phage libraries

DOI: 10.36838/IJHSR816.22

to maximize the chance of finding suitable matches for any given infection. Such an endeavor is complex and often unrealistic.

Phages also come with many pharmacokinetic unknowns. Firstly, the body's immune response might counteract the therapeutic effects of phages, as it is trained to recognize and clear phages. The body may develop antibodies that work against phages because phages are composed of densely packed genetic material and a protein coat, which can reduce phage efficacy with subsequent treatments.[26] There is also the issue of unpredictability, in that, while antibiotics and other drugs can be approached with knowledge of a reliable half-life, phages can replicate at the site of infection, leading to variability in their exact distribution. Additionally, there is still clinical uncertainty concerning how phages interact with deep-seated infections or how they may penetrate certain tissues.[27]

Bacteriophage therapies also have the potential to cause some adverse effects. For instance, in the process of lysing bacteria–specifically gram-negative bacteria–the phages may release bacterial endotoxins into the system, leading to symptoms such as fever, chills, or septic shock.[28-30] There is also the theoretical concern that a lysogenic phage could transfer genes that encode for antibiotic resistance between bacteria. This occurs because lysogenic phages, unlike lytic phages, can incorporate genetic material into the bacterial genome before replication and can therefore contribute to bacterial transformation.[15] However, this risk is largely mitigated by the fact that most phage therapies make use of lytic phages.[18-20, 28-34]

Lastly, there is the issue of regulatory hurdles. There is trouble regarding the purity and standardization of phage therapies, as a phage preparation can be composed of bacterial debris and toxins from the manufacturing process, which could be incorporated into the final product.[25] The current regulatory framework for most drugs is also not amenable to phage therapy. Guidelines are often designed around data from a single, standardized product, which proves to be a problem as wide varieties of phage therapies, such as modifiable therapies and personalized therapies, rely on a changing formula.

Despite the therapeutic potential of phage therapies, these limitations indicate that significant scientific, logistical, and regulatory challenges still hinder broader clinical usage. This suggests that further clinical research and evaluation are necessary to determine whether the practical constraints of phage therapy can be outweighed by its benefits.

Currently, modern medicine relies heavily on antimicrobial therapies to support vital procedures, including surgery, chemotherapy, organ transplantation, and intensive care, all of which depend on the reliable mitigation of infectious bacteria.[1] For this reason, despite the uncertainties surrounding phage therapy, as antimicrobial resistance continues to compromise medical procedures, interest in alternative therapies such as phage therapies has increased.[13]

Review of Clinical Studies:

Initially, a total of 368 articles were identified from PubMed, Science Direct, and Clinicaltrials.gov. After analyzing and removing articles that did not meet the inclusion criteria or met the exclusion criteria, 10 articles were identified as suitable for review. While several studies originated from PubMed or Science Direct, only 1 study was retained from Clinicaltrials.gov, as all others were either incomplete, terminated, had an unknown status, did not publish their results, or had duplicates present in the other databases. Additionally, eight of the ten studies involved clinical trials,[19, 20, 28-33] while two were case reports examining the treatment of a single patient.[18, 34]

Their results have been compiled as seen below. "PFU" indicates plaque-forming units, a measurement of the quantity of infectious particles. In this case, it indicates the number of phages given to each patient during phage treatment.

Table 1: Patient Demographics and Details of Infection in Studies Involving Phage Therapy. This table summarizes the pathogens, infection types, sample sizes, and patient histories involved in each of the reviewed studies.

Authors	Pathogen(s)	Infection Type	Sample Size	Key Patient Characteristics
Li *et al.*[18]	MDR *K. pneumoniae*	Pulmonary	1	Inpatient, multi-drug resistant infection
Leitner *et al.*[19]	*Enterococcus*, *E. coli*, *P. aeruginosa*, *Staphylococcus*, *Streptococcus*	UTI	97	Men undergoing TURP
Sarker *et al.*[20]	*E. coli* (ETEC, others)	Acute diarrhea	120	Hospitalized children
Fedorev *et al.*[28]	*Staphylococcus* spp.	Hip PJI	55	Post–hip replacement infection
Kim *et al.*[29]	*E. coli*	Uncomplicated UTI	39	Adult females; prior drug-resistant UTI
Jault *et al.*[30]	*P. aeruginosa*	Burn wound	27	Adults with infected burns
Chan *et al.*[31]	*P. aeruginosa*	Cystic fibrosis (CF) sputum infection	8	CF patients
Gupta *et al.*[32]	Mixed bacteria	Chronic wounds	20	Nonhealing wounds not responding to conventional debridement
Wright *et al.*[33]	*P. aeruginosa*	Chronic otitis	24	Refractory otitis externa
Nick *et al.*[34]	*M. abscessus*	Pulmonary (CF)	1	Severe cystic fibrosis with multidrug-resistant *P. aeruginosa*

The demographic data from Table 1 indicate that the majority of recent phage therapy trials involve adults, although there were a few studies that involved children with chronic diarrhea or children with chronic otitis.[20, 33] Looking at the patients' medical histories, it is clear that phage therapy was often used as a last resort drug to treat drug-resistant and recurrent infections, or in cases where standard therapies had proven ineffective. [18, 19, 29, 32, 34] Instances of trials involving chronic conditions–such as cystic fibrosis, joint replacement, chronic wounds, or chronic otitis–are also prevalent, indicating phage therapy is being tested in settings where biofilms or resistance would complicate standard care.[28, 31-34]

Table 2: Outcomes of Phage Treatment in Studies Involving Phage Therapy. This table compares treatment outcomes and safety profiles across the reviewed studies.

Authors	Adverse Events	Treatment Outcome
Li *et al.*[18]	None reported	Clinical improvement; emergence of phage-resistant strains with single phage treatment, but treatment with the phage cocktail resulted in improvement
Leitner *et al.*[19]	No serious AEs	Non-inferior to antibiotics; not superior to placebo
Sarker *et al.*[20]	None attributable	No clinical benefit of either phage treatment or standard of care
Fedorev *et al.*[28]	2 instances of transient fever	Phage therapy displayed a lower relapse rate compared to antibiotics
Kim *et al.*[29]	Mild AEs; more with higher dose	Rapid bacterial clearance; symptom resolution
Jault *et al.*[30]	Similar AEs to the standard of care	Slower bacterial reduction than the standard of care
Chan *et al.*[31]	2 pulmonary exacerbations, 1 hospitalization	No superiority compared to placebo
Gupta *et al.*[32]	None reported	Significant wound healing
Wright *et al.*[33]	None related	Reduced bacterial counts; symptom improvement
Nick *et al.*[34]	Neutralizing antibodies to 1 phage (did not prevent benefit)	Sustained clinical improvement

Table 2 indicates that overall, adverse events were uncommon and generally mild. Some mild AEs include tachycardia and afebrile chills,[29] pulmonary exacerbations,[31] transient fever,[28] and other events.[30] Multiple studies indicated that no adverse events occurred.[18, 20, 32, 33] Nick *et al.* reported neutralizing antibodies but without any loss of benefit.[34]

There were several trials that produced favorable results with phage therapy.[18, 28, 29, 32-34] These are indicated by reduced bacterial counts, minimal relapse rates, and clinical improvement as indicated in the table.

Other trials indicate that phage therapy does not have a significantly higher efficacy than standard care, antibiotics, or placebo treatments. These include Chan *et al.*, where both placebo and study groups performed similarly, but the placebo groups reported a higher quality of life.[31] Leitner *et al.* and Sarker *et al.* both report no significant advantages or disadvantages to using phage therapy over other treatments.[19, 20] Jault *et al.* notes that while phage therapy had a similar success rate to the standard of care, the phage therapy group had a much slower median reduction rate of bacterial burden, and that low concentrations had insufficient efficacy.[30] Kim *et al.* observed a similar linkage between dosage and treatment efficacy, noting that patients experienced more adverse events at higher doses of phage treatment.[29]

Sarker *et al.* was the only study in which phage therapy produced no notable improvement in the patient at all.[20] However, this result was attributed to the fact that only half the planned patients were enrolled by the interim analysis, and previously, they had observed no *in vivo* replication of the phage, which would significantly inhibit the therapy's effectiveness. On the other hand, most other studies performed or referred to *in vitro* or *in vivo* testing in model organisms prior to phage therapy application, either to assess the therapy early on or to select the phages to be used within the phage cocktail. In the specific case of Chan *et al.*, phage cocktail compositions were personalized for each patient based on results from these tests.[31] This indicates that for phage therapy to be successful, prior assessment of phages through *in vivo* or *in vitro* testing is a prerequisite.

Table 3: Details of Phage Treatment in Studies Involving Phage Therapy. This table summarizes the details of the phage formulations, delivery methods, and dosing strategies used in the reviewed studies.

Authors	Phage Strategy	Route	Approx. Dose	Antibiotics
Li *et al.*[18]	Single phage treatment, later switched to dual phage	Inhalation	10^9 PFU	Continued
Leitner *et al.*[19]	Commercial cocktail (Pyophage)	Intravesical	10^4–10^5 PFU	Standard care
Sarker *et al.*[20]	Commercial cocktails (T4: 11 phages, Microgen ColiProteus: 17 phages)	Oral	~10^8–10^9 PFU	None
Fedorev *et al.*[28]	Commercial cocktail (4 phages)	Local + injection	≥10^5 PFU/mL	Systemic antibiotics
Kim *et al.*[29]	Cocktail (6 phages)	Intraurethral, IV, oral	10^8–10^{12} PFU	TMP-SMX
Jault *et al.*[30]	Cocktail (12 phages)	Topical	10^2–10^6 PFU/mL	Optional
Chan *et al.*[31]	Personalized cocktails (2-3 phages)	Inhalation	3 mL × 7 days	Commonly colistin
Gupta *et al.*[32]	Customized cocktail (20 phages)	Topical	10^9 PFU	Prior antibiotics
Wright *et al.*[33]	Cocktail (6 phages)	Topical (ear)	10^5 PFU/phage	None
Nick *et al.*[34]	Dual phage	IV	10^8–10^9 PFU	Concomitant

As seen in Table 3, treatments vary between commercially available phages–such as Pyophage and Microgen ColiProteus[19, 20]–engineered phages, and customized cocktails, demonstrating the current diversity of available phage therapies.

Many routes of administration were utilized. They included intravenous,[29,34] respiratory,[18] oral,[20, 29] or intraurethral,[29] but topical treatments–such as intravesical,[19] bone cement,[28] ear drops,[33] dressings,[30] or direct topical[32]–proved to be the most common. The majority of these cases were because topical treatment was simply the most practical administration route, as these studies pertain to burns, wounds, ear infections, etc.

Jault *et al.* do claim that topical treatments could reduce the frequency of adverse effects.[30] Despite this, the review found that the frequency of adverse events from studies using topical treatments is still comparable to those that do not.

The dosages and concentrations were also highly varied. They ranged from 10^2 PFU/mL[30] to 10^{12} PFU in the urethral treatment from Kim *et al.*[29] High doses were often used for systemic or severe infections,[29, 34] while lower or moderate doses were used more frequently in topical treatments.

The majority of studies utilized antibiotics in conjunction with phage therapy, except Sarker *et al.* and Wright *et al.*[20,33] Jault *et al.* allowed antibiotics at the discretion of the physician, depending on the patient's needs.[30] This may have been because of the previously discussed possibility of synergistic activity between bacteriophages and antibiotics. However, when comparing the efficacy data of the trials that employed antibiotics to those that did not, no obvious distinction is found, which makes it unclear how much of an impact the administration of antibiotics actually had. These varied results can be partly attributed to inconsistencies in trial structure.

Regarding the issue of phage therapy producing phage resistance, only Li *et al.* indicated phage resistance occurring in the patient.[18] Li *et al.* was also the only study to treat the patient with a single phage treatment.[18] Phage resistance developed in response to the single phage treatment, but was resolved when the patient switched to a cocktail treatment. The lack of comparable studies limits the generalizability of these results. However, this indicates a possible avenue for future research into phage-resistant infections, and also resolves one of the major drawbacks of phage therapy that was previously discussed.

Additionally, many of the studies using antibiotics in combinations with phages could have worked to prevent resistance, as well as increasing the efficacy of the study, as antibiotics and phages have previously been shown to produce a synergistic effect on each other.[19] However, it also reflects that a high degree of clinical caution is still present.

Lastly, phage therapy is the most successful in cases involving localized, chronic biofilm-associated infections.[18, 28, 32-34] Most likely, this is because these infections were all localized, not systemic, reducing variability in immune-related clearance. Moreover, they involved biofilms, for which phage therapy has already been demonstrated to be proficient at tackling.[24] They also involved fairly predictable pathogens, such as *P. aeruginosa* or *S. aureus*, which allowed for the easy selection of the appropriate phages from a phage bank. All of these aspects align clearly with the predicted behavior of phage therapies based

DOI: 10.36838/IJHSR816.22

on their previously discussed advantages and disadvantages, indicating that, as phage therapy grows in commercial popularity, it will most likely be first implemented for infections similar to these: localized, biofilm-associated infections where standard antibiotic regimens have failed.

Current Attitudes Towards Phage Therapy:

There are currently several mixed opinions regarding phage therapy. On one hand, there is currently a steady increase in the number of clinical trials related to phage therapy.[25] The focus is usually on therapies targeting high-priority bacteria such as *P. aeruginosa* and *S. aureus*. This creates an optimistic outlook for the future of phage therapy as a more broadly utilized commercial treatment. Currently, though, phage therapy in the United States and Western Europe is normally employed as part of compassionate use cases. These cases are ones involving patients with life-threatening conditions who have not benefited from traditional treatment courses.[35] Success of these compassionate use cases[18, 34] improves the confidence held in phage therapy by researchers and physicians.

Currently, surveys regarding the awareness of phage therapy reveal that both the general public and physicians are not very familiar with phage therapy as a treatment option. However, the study also noted that patients with specific conditions, such as cystic fibrosis, did show strong interest in participating in clinical trials once they were given more information about phage therapies.[36]

Despite these positive outlooks, there are still many challenges and skepticism that impede the progress of phage therapy. One prominent issue is that of data access. The high specificity of phages means that in order to treat a patient, they need to receive either an extremely broad commercial, fixed treatment or a personalized phage cocktail. In order to personalize the cocktail, the hospital or the pharmacy must have access to a large and diverse bank of phages, as previously mentioned, which is an endeavor that can be expensive and impractical.[25] The regulatory hurdles that result from phage therapy's differences from traditional medications also create skepticism about how worthwhile it is to invest time in developing new therapies when there is little existing regulatory framework for treatments of this kind.

■ Conclusion

The recent resurgence of interest in bacteriophage therapy demonstrates the rising need to find alternatives to conventional antibiotics. Based on the reviewed literature and studies, phage therapy exists in a nuanced landscape where regulatory and logistical challenges counterbalance its applications and efficacy.

Based on the compiled clinical studies, phage therapy is particularly effective in situations where conventional antibiotics fail, such as biofilm-associated cases, chronic wounds, and cases involving multi-drug resistant pathogens like *P. aeruginosa*, *S. aureus*, and *K. pneumoniae*.[18, 28, 29, 32-34] Their tendency to replicate at the infection site and their ability to act synergistically alongside antibiotics also speaks to the benefits of phage therapy and combination approaches over antibiotic courses alone. Adverse effects, if any, were observed to be generally mild, suggesting the treatments' safety when under controlled conditions.

However, the application of phage therapy in clinical settings remains dubious. The narrow host range of phages creates a vast array of problems when trying to formulate effective therapies, as wide-ranging fixed formulas are limited in their potency and personalized therapies require the support of well-constructed phage libraries, along with a significant amount of time and labor. This–along with shaky pharmacokinetics, immunological interactions, and regulatory frameworks that are not yet equipped to handle variable treatments–limits any broader applications of phage therapy that extend beyond compassionate use cases. The high variability among clinical trials regarding trial size, screening processes, and methodology also indicates that while research into phage therapy is growing, the field still remains in its infancy and lacks standardization.

Broader use would require several systemic changes to be made. Clinical trials need to develop standardized protocols that manage dosing, administration routes, and monitoring criteria. This will allow for easier synthesis of data and facilitate regulatory approval. It is also important to expand phage libraries and maintain broad phage repositories. This will improve accessibility, shorten treatment delays, and support more personalized formulas. Combining phages with antibiotics, as many trials have already done, should also become a standard practice, as this will exploit phage-antibiotic synergy to produce more efficient results.

The most critical step for phage therapy is long-term safety studies and continuous monitoring of phage resistance patterns. These are critical for sustainable implementation. Regulatory agencies should also consider introducing approval pathways for phage therapies that accommodate their unique drug characteristics, allowing for the treatment to receive approval without compromising safety. Finally, broader education initiatives targeting both providers and patients can help improve awareness and practical use of phage therapy. All of these initiatives will ensure that phage therapy can be applied effectively and ethically.

■ Acknowledgments

I would like to express my gratitude to all those who helped this paper come to fruition. In particular, I would like to thank Professor Prahlad Parajuli, Professor Kay Diaz, and Professor Virgel Torremocha for all their guidance and support with reviewing, editing, and guiding me through the publication process for this paper. Without their help, none of this would have been possible.

■ References

1. Llor, C.; Bjerrum, L. Antimicrobial Resistance: Risk Associated with Antibiotic Overuse and Initiatives to Reduce the Problem. *Therapeutic Advances in Drug Safety* **2014**, *5* (6), 229–241.
2. Di Pietro, M.; Filardo, S.; Sessa, R. Editorial for the Special Issue "Antibacterial Activity of Drug-Resistant Strains." *Interna-*

tional journal of molecular sciences **2024**, *25* (3), 1878. https://doi.org/10.3390/ijms25031878.
3. Liu, C. G.; Green, S. I.; Min, L.; Clark, J. R.; Salazar, K. C.; Terwilliger, A. L.; Kaplan, H. B.; Trautner, B. W.; Ramig, R. F.; Maresso, A. W. Phage-Antibiotic Synergy Is Driven by a Unique Combination of Antibacterial Mechanism of Action and Stoichiometry. *mBio* **2020**, *11* (4). https://doi.org/10.1128/mBio.01462-20.
4. Wittebole, X.; De Roock, S.; Opal, S. M. A Historical Overview of Bacteriophage Therapy as an Alternative to Antibiotics for the Treatment of Bacterial Pathogens. *Virulence* **2013**, *5* (1), 226–235. https://doi.org/10.4161/viru.25991.
5. Barron, M. *Phage Therapy: Past, Present, and Future*. Asm.org. https://asm.org/articles/2022/august/phage-therapy-past.
6. Chanishvili, N. *Chapter 1 - Phage Therapy—History from Twort and d'Herelle Through Soviet Experience to Current Approaches*. ScienceDirect. https://www.sciencedirect.com/science/article/abs/pii/B9780123944382000013.
7. Fujiki, J.; Schnabl, B. Phage Therapy: Targeting Intestinal Bacterial Microbiota for the Treatment of Liver Diseases. *JHEP reports* **2023**, *5* (12), 100909–100909. https://doi.org/10.1016/j.jhepr.2023.100909.
8. Le, S.; Yao, X.; Lu, S.; Tan, Y.; Rao, X.; Li, M.; Jin, X.; Wang, J.; Zhao, Y.; Wu, N. C.; Lux, R.; He, X.; Shi, W.; Hu, F. Chromosomal DNA Deletion Confers Phage Resistance to Pseudomonas Aeruginosa. *Scientific Reports* **2014**, *4* (1), 4738. https://doi.org/10.1038/srep04738.
9. Chung, K. M.; Nang, S. C.; Tang, S. S. The Safety of Bacteriophages in Treatment of Diseases Caused by Multidrug-Resistant Bacteria. *Pharmaceuticals* **2023**, *16* (10), 1347. https://doi.org/10.3390/ph16101347.
10. Wang, Q.; Wang, M.; Yang, Q.; Feng, L.; Zhang, H.; Wang, R.; Wang, R. The Role of Bacteriophages in Facilitating the Horizontal Transfer of Antibiotic Resistance Genes in Municipal Wastewater Treatment Plants. *Water Research* **2024**, *268*, 122776. https://doi.org/10.1016/j.watres.2024.122776.
11. Chiang, Y. N.; Penadés, J. R.; Chen, J. Genetic Transduction by Phages and Chromosomal Islands: The New and Noncanonical. *PLOS Pathogens* **2019**, *15* (8), e1007878. https://doi.org/10.1371/journal.ppat.1007878.
12. Haaber, J.; Leisner, J. J.; Cohn, M. T.; Catalan-Moreno, A.; Nielsen, J. B.; Westh, H.; Penadés, J. R.; Ingmer, H. Bacterial Viruses Enable Their Host to Acquire Antibiotic Resistance Genes from Neighbouring Cells. *Nature Communications* **2016**, *7* (1). https://doi.org/10.1038/ncomms13333.
13. Lin, D. M.; Koskella, B.; Lin, H. C. Phage Therapy: An Alternative to Antibiotics in the Age of Multi-Drug Resistance. *World Journal of Gastrointestinal Pharmacology and Therapeutics* **2017**, *8* (3), 162–173. https://doi.org/10.4292/wjgpt.v8.i3.162.
14. Wagh, R. V.; Priyadarshi, R.; Rhim, J.-W. Novel Bacteriophage-Based Food Packaging: An Innovative Food Safety Approach. *Coatings* **2023**, *13* (3), 609. https://doi.org/10.3390/coatings13030609.
15. Kasman, L. M.; Porter, L. D. *Bacteriophages*. National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK493185/.
16. Clokie, M. R. J.; Millard, A. D.; Letarov, A. V.; Heaphy, S. Phages in Nature. *Bacteriophage* **2011**, *1* (1), 31–45. https://doi.org/10.4161/bact.1.1.14942.
17. Dicks, L.; Vermeulen, W. Bacteriophage–Host Interactions and the Therapeutic Potential of Bacteriophages. *Viruses* **2024**, *16* (3), 478–478. https://doi.org/10.3390/v16030478.
18. Li, J.; Yan, B.; He, B.; Li, L.; Zhou, X.; Wu, N.; Wang, Q.; Guo, X.; Zhu, T.; Qin, J. Development of Phage Resistance in Multidrug-Resistant Klebsiella Pneumoniae Is Associated with Reduced Virulence: A Case Report of a Personalised Phage Therapy. *Clinical Microbiology and Infection* **2023**. https://doi.org/10.1016/j.cmi.2023.08.022.
19. Leitner, L.; Ujmajuridze, A.; Chanishvili, N.; Goderdzishvili, M.; Chkonia, I.; Rigvava, S.; Chkhotua, A.; Changashvili, G.; McCallin, S.; Schneider, M. P.; Liechti, M. D.; Mehnert, U.; Bachmann, L. M.; Sybesma, W.; Kessler, T. M. Intravesical Bacteriophages for Treating Urinary Tract Infections in Patients Undergoing Transurethral Resection of the Prostate: A Randomised, Placebo-Controlled, Double-Blind Clinical Trial. *The Lancet Infectious Diseases* **2020**, *0* (0). https://doi.org/10.1016/S1473-3099(20)30330-3.
20. Sarker, S. A.; Sultana, S.; Reuteler, G.; Moine, D.; Descombes, P.; Charton, F.; Bourdin, G.; McCallin, S.; Ngom-Bru, C.; Neville, T.; Akter, M.; Huq, S.; Qadri, F.; Talukdar, K.; Kassam, M.; Delley, M.; Loiseau, C.; Deng, Y.; El Aidy, S.; Berger, B. Oral Phage Therapy of Acute Bacterial Diarrhea with Two Coliphage Preparations: A Randomized Trial in Children from Bangladesh. *EBioMedicine* **2016**, *4*, 124–137. https://doi.org/10.1016/j.ebiom.2015.12.023.
21. Abedon, S. T.; Kuhl, S. J.; Blasdel, B. G.; Kutter, E. M. Phage Treatment of Human Infections. *Bacteriophage* **2011**, *1* (2), 66–85. https://doi.org/10.4161/bact.1.2.15845.
22. Nikolich, M. P.; Filippov, A. A. Bacteriophage Therapy: Developments and Directions. *Antibiotics* **2020**, *9* (3), 135. https://doi.org/10.3390/antibiotics9030135.
23. Maciejewska, B.; Olszak, T.; Drulis-Kawa, Z. Applications of Bacteriophages versus Phage Enzymes to Combat and Cure Bacterial Infections: An Ambitious and Also a Realistic Application? *Applied Microbiology and Biotechnology* **2018**, *102* (6), 2563–2581. https://doi.org/10.1007/s00253-018-8811-1.
24. Liu, S.; Lu, H.; Zhang, S.; Shi, Y.; Chen, Q. Phages against Pathogenic Bacterial Biofilms and Biofilm-Based Infections: A Review. *Pharmaceutics* **2022**, *14* (2), 427. https://doi.org/10.3390/pharmaceutics14020427.
25. Zalewska-Piątek, B. Phage Therapy—Challenges, Opportunities and Future Prospects. *Pharmaceuticals* **2023**, *16* (12), 1638. https://doi.org/10.3390/ph16121638.
26. Dabrowska, K.; Miernikiewicz, P.; Piotrowicz, A.; Hodyra, K.; Owczarek, B.; Lecion, D.; Kazmierczak, Z.; Letarov, A.; Gorski, A. Immunogenicity Studies of Proteins Forming the T4 Phage Head Surface. *Journal of Virology* **2014**, *88* (21), 12551–12557. https://doi.org/10.1128/jvi.02043-14.
27. Nilsson, A. S. Pharmacological Limitations of Phage Therapy. *Upsala Journal of Medical Sciences* **2019**, *124* (4), 218–227. https://doi.org/10.1080/03009734.2019.1688433.
28. Fedorov, E.; Samokhin, A.; Kozlova, Y.; Kretien, S.; Sheraliev, T.; Morozova, V.; Tikunova, N.; Kiselev, A.; Pavlov, V. Short-Term Outcomes of Phage-Antibiotic Combination Treatment in Adult Patients with Periprosthetic Hip Joint Infection. *Viruses* **2023**, *15* (2), 499. https://doi.org/10.3390/v15020499.
29. Kim, P.; Sanchez, A. M.; Penke, T. J. R.; Tuson, H. H.; Kime, J. C.; McKee, R. W.; Slone, W. L.; Conley, N. R.; McMillan, L. J.; Prybol, C. J.; Garofolo, P. M. Safety, Pharmacokinetics, and Pharmacodynamics of LBP-EC01, a CRISPR-Cas3-Enhanced Bacteriophage Cocktail, in Uncomplicated Urinary Tract Infections due to Escherichia Coli (ELIMINATE): The Randomised, Open-Label, First Part of a Two-Part Phase 2 Trial. *The Lancet Infectious Diseases* **2024**. https://doi.org/10.1016/s1473-3099(24)00424-9.
30. Jault, P.; Leclerc, T.; Jennes, S.; Pirnay, J. P.; Que, Y.-A.; Resch, G.; Rousseau, A. F.; Ravat, F.; Carsin, H.; Le Floch, R.; Schaal, J. V.; Soler, C.; Fevre, C.; Arnaud, I.; Bretaudeau, L.; Gabard, J. Efficacy and Tolerability of a Cocktail of Bacteriophages to Treat Burn Wounds Infected by Pseudomonas Aeruginosa (PhagoBurn): A Randomised, Controlled, Double-Blind Phase 1/2 Trial. *The Lan-*

DOI: 10.36838/IJHSR816.22

cet Infectious Diseases **2019**, *19* (1), 35–45. https://doi.org/10.1016/s1473-3099(18)30482-1.
31. Chan, B. K.; Stanley, G. L.; Kortright, K. E.; Vill, A. C.; Modak, M.; Ott, I. M.; Sun, Y.; Würstle, S.; Grun, C. N.; Kazmierczak, B. I.; Rajagopalan, G.; Harris, Z. M.; Britto, C. J.; Stewart, J.; Talwalkar, J. S.; Appell, C. R.; Chaudary, N.; Jagpal, S. K.; Jain, R.; Kanu, A. Personalized Inhaled Bacteriophage Therapy for Treatment of Multidrug-Resistant Pseudomonas Aeruginosa in Cystic Fibrosis. *Nature Medicine* **2025**. https://doi.org/10.1038/s41591-025-03678-8.
32. Gupta, P.; Singh, H. S.; Shukla, V. K.; Nath, G.; Bhartiya, S. K. Bacteriophage Therapy of Chronic Nonhealing Wound: Clinical Study. *The International Journal of Lower Extremity Wounds* **2019**, *18* (2), 171–175. https://doi.org/10.1177/1534734619835115.
33. Wright, A.; Hawkins, C. H.; Änggård, E. E.; Harper, D. R. A Controlled Clinical Trial of a Therapeutic Bacteriophage Preparation in Chronic Otitis due to Antibiotic-ResistantPseudomonas Aeruginosa; a Preliminary Report of Efficacy. *Clinical Otolaryngology* **2009**, *34* (4), 349–357. https://doi.org/10.1111/j.1749-4486.2009.01973.x.
34. Nick, J. A.; Dedrick, R. M.; Gray, A. L.; Vladar, E. K.; Smith, B. E.; Freeman, K. G.; Malcolm, K. C.; Epperson, L. E.; Hasan, N. A.; Hendrix, J.; Callahan, K.; Walton, K.; Vestal, B.; Wheeler, E.; Rysavy, N. M.; Poch, K.; Caceres, S.; Lovell, V. K.; Hisert, K. B.; de Moura, V. C. Host and Pathogen Response to Bacteriophage Engineered against Mycobacterium Abscessus Lung Infection. *Cell* **2022**, *185* (11), 1860-1874.e12. https://doi.org/10.1016/j.cell.2022.04.024.
35. McCallin; Sacher; Zheng; Chan. Current State of Compassionate Phage Therapy. *Viruses* **2019**, *11* (4), 343. https://doi.org/10.3390/v11040343.
36. Gandhi, S.; Edwards, D.; Emmert, K.; Large, B. Exploration of Providers' Perceptions and Attitudes toward Phage Therapy and Intentions for Future Adoption as an Alternative to Traditional Antibiotics in the US—a Cross-Sectional Study. *International Journal of Environmental Research and Public Health* **2025**, *22* (7), 1139–1139. https://doi.org/10.3390/ijerph22071139.

■ Author

Ananya Anand is a high school junior at Adlai E. Stevenson High School with interests in microbiology, infectious diseases, and biomedical research. She is passionate about advancing clinical research and plans to pursue a career in medicine and the biological sciences.